The information contained on this page is intended
for US healthcare professionals only.  Patient siteFREE SAMPLES/COUPONS

The information contained on this page is intended
for US healthcare professionals only.  Patient siteFREE SAMPLES/COUPONS

OPPORTUNITY FOR INNOVATION IN ASPIRIN DELIVERY

Plain aspirin is associated with local GI injury, which can be asymptomatic1
In patients using aspirin for secondary prevention, discontinuation led to a 46% higher rate of cardiovascular events2
According to aspirin professional class labeling, enteric coated aspirin products are erratically absorbed from the GI tract3

There hasn’t been innovation in the mechanism of
aspirin delivery in over 50 years

References:

  1. Cryer B, Mahaffey KW. Gastrointestinal ulcers, role of aspirin, and clinical outcomes: pathobiology, diagnosis, and treatment. J Multidiscip Healthc. 2014;7:137-146.
  2. Sundström J, Hedberg J, Thuresson M, Aarskog P, Johannesen KM, Oldgren J. Low-dose aspirin discontinuation and risk of cardiovascular events: a Swedish nationwide, population-based cohort study. Circulation. 2017;136(13):1183-1192.
  3. CFR — Code of Federal Regulations Title 21. Internal Analgesic, Antipyretic, and Antirhreumatic Drug Products for Over-the-Counter Human Use. Food and Drug Administration; US Dept of Health and Human Services; 2015.

Learn how
VAZALORE works
 

Read VAZALORE 325 mg clinical results
 
 

Access VAZALORE
resources